Publication: Targets and strategies for vaccine development against dengue viruses
2
Issued Date
2021-12-01
Resource Type
ISSN
19506007
07533322
07533322
Other identifier(s)
2-s2.0-85116661735
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biomedicine and Pharmacotherapy. Vol.144, (2021)
Suggested Citation
Wen Hung Wang, Aspiro Nayim Urbina, Chih Yen Lin, Zih Syuan Yang, Wanchai Assavalapsakul, Arunee Thitithanyanont, Po Liang Lu, Yen Hsu Chen, Sheng Fan Wang Targets and strategies for vaccine development against dengue viruses. Biomedicine and Pharmacotherapy. Vol.144, (2021). doi:10.1016/j.biopha.2021.112304 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78933
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Targets and strategies for vaccine development against dengue viruses
Abstract
Dengue virus (DENV) is a global health threat causing about half of the worldwide population to be at risk of infection, especially the people living in tropical and subtropical area. Although the dengue disease caused by dengue virus (DENV) is asymptomatic and self-limiting in most people with first infection, increased severe dengue symptoms may be observed in people with heterotypic secondary DENV infection. Since there is a lack of specific antiviral medication, the development of dengue vaccines is critical in the prevention and control this disease. Several targets and strategies in the development of dengue vaccine have been demonstrated. Currently, Dengvaxia, a live-attenuated chimeric yellow-fever/tetravalent dengue vaccine (CYD-TDV) developed by Sanofi Pasteur, has been licensed and approved for clinical use in some countries. However, this vaccine has demonstrated low efficacy in children and dengue-naïve individuals and also increases the risk of severe dengue in young vaccinated recipients. Accordingly, many novel strategies for the dengue vaccine are under investigation and development. Here, we conducted a systemic literature review according to PRISMA guidelines to give a concise overview of various aspects of the vaccine development process against DENVs, mainly targeting five potential strategies including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral-vector vaccine, and DNA vaccine. This study offers the comprehensive view of updated information and current progression of immunogen selection as well as strategies of vaccine development against DENVs.